Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pancreatic cancer
Pharma
Astellas lifts forecast as Vyloy surge counters trial miss
Alongside a recorded loss pinned on Vyloy's pancreatic cancer setback, Astellas also terminated ASP4396, a phase 1 KRAS G12D program.
Angus Liu
Feb 5, 2026 11:00am
Merus' Bizengri wins FDA nod as 1st drug to target NRG1+ cancers
Dec 4, 2024 6:55pm
PCI and ChiRhoClin partner to foil shortage of diagnostic drug
Nov 20, 2024 9:30am
Ipsen's Onivyde combo approved in first-line pancreatic cancer
Feb 13, 2024 4:31pm
Exelixis ends Cabometyx study after seeing dramatic improvements
Aug 24, 2023 12:54pm
Ipsen's Onivyde turns in positive results in pancreatic cancer
Jan 20, 2023 11:21am
